For women with ovarian cancer, CA 125
levels were found to correlate with tumour burden in 93% of cases.
Various alimentary canal and pelvic cancers have already been associated with the high concentrations of CA 125
in the blood8,9,15,16.
levels were determined by the electrochemiluminescence immunoassay method using the DXI 800 automatic quantitative hematology analyzer (Beckman Coulter Inc., CA, USA).
Auge et al., "HE4 a novel tumour marker for ovarian cancer: comparison with CA 125
and ROMA algorithm in patients with gynaecological diseases," Tumor Biology, vol.
Judson, "Sarcoidosis associated with an elevated serum CA 125
level: description of a case and a review of the literature," The American Journal of the Medical Sciences, vol.
For a premenopausal woman who has not completed childbearing, transvaginal ultrasonography with serum CA 125
testing can be considered.
Until recently the only discriminator was the cancer antigen 125 (CA 125
) tumour marker.
Dekker et al., "Fluctuations in CA 125
and CA 15-3 serum concentrations during spontaneous ovulatory cycles," Human Reproduction, vol.
Women cannot be screened for CA 125
levels until 35, but Janet argues this age limit should be lowered.
Irritable bowel-type symptoms and/or raised CA 125
levels do not necessarily mean you have ovarian cancer, as both of these can also be caused by other more benign conditions.
Among the tests being recommended for Arroyo are a PET scan and tumor marker tests such as alpha feto protein for the liver, varcinoembryonic antigen (CEA) for the breast and pancreas and CA 125
calcitonin for the medullary thyroid.
Serum CA 125
concentrations in patients with benign ovarian tumours.
Other diagnostic tests include a CA 125
blood test and a transvaginal ultrasound.
Results: The serum CEA and CA 125
levels were found to be significantly elevated in gastric cancer patients than in controls.
CA 15-3, CA 125
, and [beta]-2 microglobulin are three common tumor markers currently used for diagnosis, prognosis, assessment of therapeutic response, and/or to evaluate recurrence in breast and ovarian cancer and malignant lymphoproliferative disorders, respectively.